Isofol Medical AB ( (SE:ISOFOL) ) has provided an announcement.
Isofol Medical AB has commenced a clinical phase Ib/II study for its drug candidate arfolitixorin, targeting metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to optimize the drug’s efficacy through a new dosing regimen, marking a significant step towards bringing arfolitixorin to market and potentially improving treatment outcomes for patients with advanced cancers.
More about Isofol Medical AB
Isofol Medical AB is a research-based biotechnology company focused on improving the prognosis for patients with severe forms of cancer. The company is developing arfolitixorin, a drug candidate aimed at enhancing the efficacy of first-line standard treatments for various solid tumors, including colorectal cancer. Isofol Medical AB is listed on Nasdaq Stockholm.
YTD Price Performance: -15.76%
Technical Sentiment Signal: Buy
Current Market Cap: €27.86M
For an in-depth examination of ISOFOL stock, go to TipRanks’ Stock Analysis page.